AgomAb Therapeutics NV (AGMB) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Prothena is the larger company by market cap ($435.3 million vs $433.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGMB | PRTA |
|---|---|---|
| Share price | $8.80 | $8.48 |
| Market cap | $433.38M | $435.34M |
| 1-day change | -0.45% | +5.74% |
| YTD return | — | -11.20% |
| 1-year return | — | -16.62% |
| 5-year return | — | -86.64% |
| EPS (TTM) | $-2.08 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.82 | $11.80 |
| 52-week low | $7.97 | $7.73 |
| Distance from 52-week high | -50.62% | -28.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +328.07% | +152.36% |
| Average volume | 137.04K | 478.70K |
| Shares outstanding | 49.25M | 51.34M |
| Employees | 62 | 67 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About AgomAb Therapeutics NV
AGMB stock →AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
Healthcare · Biotechnology · 62 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Healthcare · Biotechnology · 67 employees
AGMB vs PRTA FAQ
Which is bigger, AgomAb Therapeutics NV or Prothena?
Prothena (PRTA) is larger, with a market capitalization of $435.34M compared with $433.38M for AgomAb Therapeutics NV (AGMB).
Are AgomAb Therapeutics NV and Prothena in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.